

## Publikationen Univ.-Prof. Dr. Bernd Neumaier

- 1. Transcranial direct current stimulation accelerates recovery of function, induces neurogenesis and recruits oligodendrocyte precursors in a rat model of stroke**  
R. Braun, R. Klein, H. L. Walter, M. Ohren, L. Freudenmacher, K. Getachew, A. Ladwig, J. Luelling, B. Neumaier, H. Endepols, R. Graf, M. Hoehn, G. R. Fink, M. Schroeter, M. A. Rueger, *Exp. Neurol.* 2016, 279, 127-136.
- 2. Glucose consumption of inflammatory cells masks metabolic deficits in the brain**  
H. Backes, M. Walberer, A. Ladwig, M. A. Rueger, B. Neumaier, H. Endepols, M. Hoehn, G. R. Fink, M. Schroeter, R. Graf, *Neuroimage* 2016, 128, 54-62.
- 3. Seyferth-Gilbert Homologation as a Route to F-18-Labeled Building Blocks: Preparation of Radiofluorinated Phenylacetylenes and Their Application in PET Chemistry**  
P. Krapf, R. Richarz, E. A. Urusova, B. Neumaier, B. D. Zlatopolskiy, *Eur. J. Org. Chem.* 2016, 430-433.
- 4. Automated synthesis of 4-[18F]fluoroanisole, [18F]DAA1106 and 4-[18F]FPhe using Cu-mediated radiofluorination under "minimalist" conditions**  
J. Zischler, P. Krapf, R. Richarz, B. D. Zlatopolskiy, B. Neumaier, *Appl. Radiat. Isot.* 2016.
- 5. Longitudinal assessment of infarct progression, brain metabolism and behavior following anterior cerebral artery occlusion in rats**  
H. Endepols, H. Mertgens, H. Backes, U. Himmelreich, B. Neumaier, R. Graf, G. Mies, *J Neurosci Methods* 2015, 253, 279-291.
- 6. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer**  
J. Schoettle, S. Chatterjee, C. Volz, M. Siobal, A. Florin, D. Rokitta, Y. Hinze, F. Dietlein, D. Plenker, K. Koenig, K. Albus, J. M. Heuckmann, D. Rauh, T. Franz, B. Neumaier, U. Fuhr, L. C. Heukamp, R. T. Ullrich, *Oncotarget* 2015, 6, 38458-38468.
- 7. Developments in oncological positron emission tomography/computed tomography assessment**  
C. Kobe, R. Boellaard, J. Wolf, G. Kuhnert, M. Dietlein, B. Neumaier, A. Drzezga, D. Kahraman, *J Thorac Dis* 2015, 7, E637-639.
- 8. A Practical One-Pot Synthesis of Positron Emission Tomography (PET) Tracers via Nickel-Mediated Radiofluorination**  
B. D. Zlatopolskiy, J. Zischler, E. A. Urusova, H. Endepols, E. Kordys, H. Frauendorf, F. M. Mottaghy, B. Neumaier, *ChemistryOpen* 2015, 4, 457-462.
- 9. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer**  
M. Dietlein, C. Kobe, G. Kuhnert, S. Stockter, T. Fischer, K. Schomacker, M. Schmidt, F. Dietlein, B. D. Zlatopolskiy, P. Krapf, R. Richarz, S. Neubauer, A. Drzezga, B. Neumaier, *Mol. Imaging Biol.* 2015, 17, 575-584.
- 10. In vivo analysis of neuroinflammation in the late chronic phase after experimental stroke**  
H. L. Walter, M. Walberer, M. A. Rueger, H. Backes, D. Wiedermann, M. Hoehn, B. Neumaier, R. Graf, G. R. Fink, M. Schroeter, *Neuroscience* 2015, 292, 71-80.
- 11. Copper-mediated aromatic radiofluorination revisited: efficient production of PET tracers on a preparative scale**

- B. D. Zlatopolskiy, J. Zischler, P. Krapf, F. Zarrad, E. A. Urusova, E. Kordys, H. Endepols, B. Neumaier, *Chemistry* 2015, 21, 5972-5979.
12. **Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo**  
J. Hucklenbroich, R. Klein, B. Neumaier, R. Graf, G. R. Fink, M. Schroeter, M. A. Rueger, *Stem Cell Res Ther* 2014, 5, 100.
  13. **In-vivo detection of inflammation and neurodegeneration in the chronic phase after permanent embolic stroke in rats**  
M. Walberer, S. U. Jantzen, H. Backes, M. A. Rueger, M. H. Keuters, B. Neumaier, M. Hoehn, G. R. Fink, R. Graf, M. Schroeter, *Brain Res.* 2014, 1581, 80-88.
  14. **Acute and sustained effects of methylphenidate on cognition and presynaptic dopamine metabolism: an [18F]FDOPA PET study**  
I. Schabram, K. Henkel, S. Mohammadkhani Shali, C. Dietrich, J. Schmaljohann, O. Winz, S. Prinz, L. Rademacher, B. Neumaier, M. Felzen, Y. Kumakura, P. Cumming, F. M. Mottaghy, G. Grunder, I. Vernaleken, *J. Neurosci.* 2014, 34, 14769-14776.
  15. **Neither azeotropic drying, nor base nor other additives: a minimalist approach to (18)F-labeling**  
R. Richarz, P. Krapf, F. Zarrad, E. A. Urusova, B. Neumaier, B. D. Zlatopolskiy, *Org. Biomol. Chem.* 2014, 12, 8094-8099.
  16. **The integrity of the cholinergic system determines memory performance in healthy elderly**  
N. Richter, I. Allendorf, O. A. Onur, L. Kracht, M. Dietlein, M. Tittgemeyer, B. Neumaier, G. R. Fink, J. Kukolja, *Neuroimage* 2014, 100, 481-488.
  17. **Neural correlates of sensorimotor gating: a metabolic positron emission tomography study in awake rats**  
C. Rohleder, F. Jung, H. Mertgens, D. Wiedermann, M. Sue, B. Neumaier, R. Graf, F. M. Leweke, H. Endepols, *Front Behav Neurosci* 2014, 8, 178.
  18. **Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer**  
S. Chatterjee, C. Wiczorek, J. Schottle, M. Siobal, Y. Hinze, T. Franz, A. Florin, J. Adamczak, L. C. Heukamp, B. Neumaier, R. T. Ullrich, *Cancer Res.* 2014, 74, 2816-2824.
  19. **The synthetic NCAM mimetic peptide FGL mobilizes neural stem cells in vitro and in vivo**  
R. Klein, S. Blaschke, B. Neumaier, H. Endepols, R. Graf, M. Keuters, J. Hucklenbroich, M. Albrechtsen, S. Rees, G. R. Fink, M. Schroeter, M. A. Rueger, *Stem Cell Rev* 2014, 10, 539-547.
  20. **Synthesis of 18F-labelled beta-lactams by using the Kinugasa reaction**  
B. D. Zlatopolskiy, P. Krapf, R. Richarz, H. Frauendorf, F. M. Mottaghy, B. Neumaier, *Chemistry* 2014, 20, 4697-4703.
  21. **Nondestructive monitoring of tissue-engineered constructs**  
J. Frese, A. Morgenroth, M. E. Mertens, S. Koch, L. Rongen, A. T. Vogg, B. D. Zlatopolskiy, B. Neumaier, V. N. Gesche, T. Lammers, T. Schmitz-Rode, P. Mela, S. Jockenhoevel, F. M. Mottaghy, F. Kiessling, *Biomed Tech (Berl)* 2014, 59, 165-175.
  22. **Recent trends in pharmaceutical radiochemistry for molecular PET imaging**  
O. Prante, R. Haubner, P. Riss, B. Neumaier, *Biomed Res Int* 2014, 2014, 890540.
  23. **Non-invasive imaging of glioma vessel size and densities in correlation with tumour cell proliferation by small animal PET and MRI**

- T. Viel, P. Boehm-Sturm, S. Rapic, P. Monfared, B. Neumaier, M. Hoehn, A. H. Jacobs, *Eur. J. Nucl. Med. Mol. Imaging* 2013, 40, 1595-1606.
24. **Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib**  
M. Scheffler, T. Zander, L. Nogova, C. Kobe, D. Kahraman, M. Dietlein, I. Papachristou, L. Heukamp, R. Buttner, R. Boellaard, A. A. Lammertsma, S. Querings, E. Stoelben, W. Engel-Riedel, B. Neumaier, J. Wolf, *PLoS One* 2013, 8, e53081.
25. **Imaging microglial activation and glucose consumption in a mouse model of Alzheimer's disease**  
S. Rapic, H. Backes, T. Viel, M. P. Kummer, P. Monfared, B. Neumaier, S. Vollmar, M. Hoehn, A. Van der Linden, M. T. Heneka, A. H. Jacobs, *Neurobiol Aging* 2013, 34, 351-354.
26. **Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer**  
S. Chatterjee, L. C. Heukamp, M. Siobal, J. Schottle, C. Wieczorek, M. Peifer, D. Frasca, M. Koker, K. Konig, L. Meder, D. Rauh, R. Buettner, J. Wolf, R. A. Brekken, B. Neumaier, G. Christofori, R. K. Thomas, R. T. Ullrich, *J. Clin. Invest.* 2013, 123, 1732-1740.
27. **Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET**  
M. Scheffler, C. Kobe, T. Zander, L. Nogova, D. Kahraman, R. Thomas, B. Neumaier, M. Dietlein, J. Wolf, *Lung Cancer* 2012, 77, 617-620.
28. **MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab**  
M. Scheffler, M. Bos, M. L. Sos, L. Nogova, C. Mattonet, M. Gardizi, I. Papachristou, D. Kahraman, C. Kobe, R. Boellaard, A. A. Lammertsma, R. T. Ullrich, T. Persigehl, L. Heukamp, R. Buettner, T. Elter, K. Toepelt, W. Engel-Riedel, E. Stoelben, B. Neumaier, M. Dietlein, T. Zander, J. Wolf, *Onkologie* 2012, 35, 138-139.
29. **Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib**  
D. Kahraman, A. Holstein, M. Scheffler, T. Zander, L. Nogova, A. A. Lammertsma, R. Boellaard, B. Neumaier, M. Dietlein, J. Wolf, C. Kobe, *Clin Nucl Med* 2012, 37, 1058-1064.
30. **Cholinergic system function and cognition in mild cognitive impairment**  
C. Haense, E. Kalbe, K. Herholz, C. Hohmann, B. Neumaier, R. Kraus, W. D. Heiss, *Neurobiol Aging* 2012, 33, 867-877.
31. **Effects of minocycline on endogenous neural stem cells after experimental stroke**  
M. A. Rueger, S. Muesken, M. Walberer, S. U. Jantzen, K. Schnakenburg, H. Backes, R. Graf, B. Neumaier, M. Hoehn, G. R. Fink, M. Schroeter, *Neuroscience* 2012, 215, 174-183.
32. **Beyond azide-alkyne click reaction: easy access to 18F-labelled compounds via nitrile oxide cycloadditions**  
B. D. Zlatopolskiy, R. Kandler, D. Kobus, F. M. Mottaghy, B. Neumaier, *Chem Commun (Camb)* 2012, 48, 7134-7136.

33. **Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MRI**  
T. Viel, K. M. Talasila, P. Monfared, J. Wang, J. F. Jikeli, Y. Waerzeggers, B. Neumaier, H. Backes, N. Brekka, F. Thorsen, D. Stieber, S. P. Niclou, A. Winkeler, B. Tavitian, M. Hoehn, R. Bjerkvig, H. Miletic, A. H. Jacobs, J. Nucl. Med. 2012, 53, 1135-1145.
34. **Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib**  
C. Kobe, M. Scheffler, A. Holstein, T. Zander, L. Nogova, A. A. Lammertsma, R. Boellaard, B. Neumaier, R. T. Ullrich, M. Dietlein, J. Wolf, D. Kahraman, Eur. J. Nucl. Med. Mol. Imaging 2012, 39, 1117-1127.
35. **C-(4-[18F]fluorophenyl)-N-phenyl nitron: A novel 18F-labeled building block for metal free [3+2]cycloaddition**  
B. D. Zlatopolskiy, R. Kandler, F. M. Mottaghy, B. Neumaier, Appl. Radiat. Isot. 2012, 70, 184-192.
36. **Potential of early [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography for identifying hypoperfusion and predicting fate of tissue in a rat embolic stroke model**  
M. Walberer, H. Backes, M. A. Rueger, B. Neumaier, H. Endepols, M. Hoehn, G. R. Fink, M. Schroeter, R. Graf, Stroke 2012, 43, 193-198.
37. **Conflict Processing in the Rat Brain: Behavioral Analysis and Functional muPET Imaging Using [18F]Fluorodeoxyglucose**  
C. Marx, B. Lex, C. Calaminus, W. Hauber, H. Backes, B. Neumaier, G. Mies, R. Graf, H. Endepols, Front Behav Neurosci 2012, 6, 4.
38. **Monitoring therapy with erlotinib and afatinib in a patient with advanced non-small cell lung cancer and activating EGFR-mutation by sequential FLT-PET**  
M. Scheffler, C. Kobe, T. Zander, L. Nogova, B. Neumaier, M. Dietlein, J. Wolf, Onkologie 2011, 34, 154-154.
39. **Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [18F]fluorodeoxyglucose and [18F]fluorothymidine positron emission tomography**  
T. Zander, M. Scheffler, L. Nogova, C. Kobe, W. Engel-Riedel, M. Hellmich, I. Papachristou, K. Toepelt, A. Draube, L. Heukamp, R. Buettner, Y. D. Ko, R. T. Ullrich, E. Smit, R. Boellaard, A. A. Lammertsma, M. Hallek, A. H. Jacobs, A. Schlesinger, K. Schulte, S. Querings, E. Stoelben, B. Neumaier, R. K. Thomas, M. Dietlein, J. Wolf, J Clin Oncol 2011, 29, 1701-1708.
40. **Tc-99m-MIBI-negative parathyroid adenoma in primary hyperparathyroidism detected by C-11-methionine PET/CT after previous thyroid surgery**  
M. C. Schmidt, D. Kahraman, B. Neumaier, M. Ortmann, D. Stippel, Clin Nucl Med 2011, 36, 1153-1155.
41. **Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET**  
D. Kahraman, M. Scheffler, T. Zander, L. Nogova, A. A. Lammertsma, R. Boellaard, B. Neumaier, R. T. Ullrich, A. Holstein, M. Dietlein, J. Wolf, C. Kobe, J. Nucl. Med. 2011, 52, 1871-1877.
42. **Whiskers area as extracerebral reference tissue for quantification of rat brain metabolism using 18F-FDG PET: application to focal cerebral ischemia**

- H. Backes, M. Walberer, H. Endepols, B. Neumaier, R. Graf, K. Wienhard, G. Mies, J. Nucl. Med. 2011, 52, 1252-1260.
43. **Noninvasive imaging of endogenous neural stem cell mobilization in vivo using positron emission tomography**  
M. A. Rueger, H. Backes, M. Walberer, B. Neumaier, R. Ullrich, M. L. Simard, B. Emig, G. R. Fink, M. Hoehn, R. Graf, M. Schroeter, J. Neurosci. 2010, 30, 6454-6460.
44. **Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma**  
M. Luster, W. Karges, K. Zeich, S. Pauls, F. A. Verburg, H. Dralle, G. Glatting, A. K. Buck, C. Solbach, B. Neumaier, S. N. Reske, F. M. Mottaghy, Thyroid 2010, 20, 527-533.
45. **Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma**  
M. Luster, W. Karges, K. Zeich, S. Pauls, F. A. Verburg, H. Dralle, G. Glatting, A. K. Buck, C. Solbach, B. Neumaier, S. N. Reske, F. M. Mottaghy, Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 484-493.
46. **Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit**  
C. Eggers, A. Schmidt, J. Hagenah, N. Bruggemann, J. C. Klein, V. Tadic, L. Kertelge, M. Kasten, F. Binkofski, H. Siebner, B. Neumaier, G. R. Fink, R. Hilker, C. Klein, Neurology 2010, 74, 1798-1805.
47. **Synthesis and evaluation of 18F-fluoroethylated benzothiazole derivatives for in vivo imaging of amyloid plaques in Alzheimer's disease**  
B. Neumaier, S. Deisenhofer, C. Sommer, C. Solbach, S. N. Reske, F. Mottaghy, Appl. Radiat. Isot. 2010, 68, 1066-1072.
48. **Imaging reporter gene expression**  
A. H. Jacobs, P. Monfared, T. Viel, Y. Waerzeggers, D. Rudan, H. Backes, B. Neumaier, European Journal of Neurology 2009, 16, 4-4.
49. **A fully automated two-step synthesis of an 18F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors**  
D. Kobus, Y. Giesen, R. Ullrich, H. Backes, B. Neumaier, Appl. Radiat. Isot. 2009, 67, 1977-1984.
50. **Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F]FDG-PET study**  
M. Schroeter, M. A. Dennin, M. Walberer, H. Backes, B. Neumaier, G. R. Fink, R. Graf, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2009, 29, 1216-1225.
51. **Noninvasive quantification of 18F-FLT human brain PET for the assessment of tumour proliferation in patients with high-grade glioma**  
H. Backes, R. Ullrich, B. Neumaier, L. Kracht, K. Wienhard, A. H. Jacobs, Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1960-1967.
52. **Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([18F]FLT) positron emission tomography (PET)**  
R. T. Ullrich, T. Zander, B. Neumaier, M. Koker, T. Shimamura, Y. Waerzeggers, C. L. Borgman, S. Tawadros, H. Li, M. L. Sos, H. Backes, G. I. Shapiro, J. Wolf, A. H. Jacobs, R. K. Thomas, A. Winkeler, PLoS One 2008, 3, e3908.

53. **Short Communication: 18F-immuno-PET: Determination of anti-CD66 biodistribution in a patient with high-risk leukemia**  
B. Neumaier, F. M. Mottaghy, A. K. Buck, G. Glatting, N. M. Blumstein, B. Mahren, A. T. Vogg, S. N. Reske, *Cancer Biother Radiopharm* 2008, 23, 819-824.
54. **Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma**  
R. Ullrich, H. Backes, H. Li, L. Kracht, H. Miletic, K. Kesper, B. Neumaier, W. D. Heiss, K. Wienhard, A. H. Jacobs, *Clin. Cancer Res.* 2008, 14, 2049-2055.
55. **Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma**  
F. M. Mottaghy, C. Sunderkotter, R. Schubert, P. Wohlfart, N. M. Blumstein, B. Neumaier, G. Glatting, C. Ozdemir, A. K. Buck, K. Scharffetter-Kochanek, S. N. Reske, *Eur. J. Nucl. Med. Mol. Imaging* 2007, 34, 1355-1364.
56. **Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma**  
F. M. Mottaghy, C. Sunderkoetter, R. Schubert, P. Wohlfart, N. M. Blumstein, B. Neumaier, G. Glatting, C. Oezdemir, A. K. Buck, K. Scharffetter-Kochanek, S. N. Reske, *Eur. J. Nucl. Med. Mol. Imaging* 2007, 34, 1365-1365.
57. **Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT**  
A. K. Buck, C. Kratochwil, G. Glatting, M. Juweid, M. Bommer, D. Tepsic, A. T. Vogg, T. Mattfeldt, B. Neumaier, P. Moller, S. N. Reske, *Eur. J. Nucl. Med. Mol. Imaging* 2007, 34, 1775-1782.
58. **Synthesis and biodistribution of 3'-fluoro-5-[131I]iodo-2'-deoxyuridine: a comparative study of [131I]FLIdU and [18F]FLT**  
A. T. Vogg, A. K. Buck, M. Schmid, B. Neumaier, K. Wczasek, B. D. Zlatopolskiy, S. N. Reske, *Nucl. Med. Biol.* 2007, 34, 273-281.
59. **Radiation dosimetry and biodistribution of the beta-amyloid plaque imaging tracer C-11-BTA-1 in humans**  
S. Thees, B. Neumaier, G. Glatting, S. Deisenhofer, C. A. F. von Arnim, S. N. Reske, F. M. Mottaghy, *Nuklearmedizin-Nuclear Medicine* 2007, 46, 175-180.
60. **Rodiosynthesis and evaluation of C-11 BTA-1 and C-11 3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques**  
B. Neumaier, S. Deisenhofer, D. Fuerst, C. A. F. von Arnim, S. Thees, A. K. Buck, G. Glatting, G. B. Landwehrmeyer, B. J. Krouse, H. D. Mueller, C. Sommer, S. N. Reske, F. M. Mottaghy, *Nuklearmedizin-Nuclear Medicine* 2007, 46, 271-280.
61. **Labelling of a monoclonal antibody with Ga-68 using three DTPA-based bifunctional ligands and their in vitro evaluation for application in radioimmunotherapy**  
B. Koop, S. N. Reske, B. Neumaier, *Radiochim. Acta* 2007, 95, 39-42.
62. **Molecular imaging of proliferation in malignant lymphoma**  
A. K. Buck, M. Bommer, S. Stilgenbauer, M. Juweid, G. Glatting, H. Schirrmeister, T. Mattfeldt, D. Tepsic, D. Bunjes, F. M. Mottaghy, B. J. Krause, B. Neumaier, H. Dohner, P. Moller, S. N. Reske, *Cancer Res.* 2006, 66, 11055-11061.
63. **Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation**  
T. Zenz, R. F. Schlenk, G. Glatting, B. Neumaier, N. Blumstein, I. Buchmann, S. von Harsdorf, M. Ringhoffer, M. Wiesneth, F. Keller, J. Kotzerke, E. Rottinger, S. Stilgenbauer, H. Dohner, S. N. Reske, D. Bunjes, *J. Nucl. Med.* 2006, 47, 278-286.

64. **Imaging prostate cancer with C-11-choline PET/CT**  
S. N. Reske, N. M. Blumstein, B. Neumaier, H.-W. Gottfried, F. Finsterbusch, D. Kocot, P. Moeller, G. Glatting, S. Perner, J. Nucl. Med. 2006, 47, 1249-1254.
65. **Anti-CD45 monoclonal anti-body YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia**  
G. Glatting, M. Mueller, B. Koop, K. Hohl, C. Friesen, B. Neumaier, E. Berrie, P. Bird, G. Hale, N. M. Blumstein, H. Waldmann, D. Bunjes, S. N. Reske, J. Nucl. Med. 2006, 47, 1335-1341.
66. **Synthesis and evaluation of a radiometal-labeled macrocyclic chelator-derivatised thymidine analog**  
M. Schmid, B. Neumaier, A. T. J. Vogg, K. Wczasek, C. Friesen, F. M. Mottaghy, A. K. Buck, S. N. Reske, Nucl. Med. Biol. 2006, 33, 359-366.
67. **Improving binding potential analysis in 11C -Raclopride brain-PET studies using cluster analysis**  
T. Schwarzlmüller, G. Glatting, B. J. Krause, B. Neumaier, S. N. Reske, G. B. Landwehrmeyer, Journal of Neurology Neurosurgery and Psychiatry 2005, 76.
68. **SYNTHESIS OF A N-3 SUBSTITUTED THYMIDINE DERIVATIVE FOR LABELING WITH TRIVALENT RADIONUCLIDES**  
M. Schmid, A. T. J. Vogg, B. Neumaier, S. N. Reske, J. Labelled Compd. Radiopharm. 2005, 48, S303-S303.
69. **Vitrectomy for persistent diffuse diabetic macular edema**  
U. Stolba, S. Binder, D. Gruber, I. Krebs, T. Aggermann, B. Neumaier, American Journal of Ophthalmology 2005, 140, 295-301.
70. **Re-188 or Y-90-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study**  
M. Ringhoffer, N. Blumstein, B. Neumaier, G. Glatting, S. Harsdorf, I. Buchmann, M. Wiesneth, J. Kotzerke, T. Zenz, A. K. Buck, P. Schauwecker, S. Stilgenbauer, H. Dohner, S. N. Reske, D. Bunjes, British Journal of Haematology 2005, 130, 604-613.
71. **Clinical relevance of imaging proliferative activity in lung nodules**  
A. K. Buck, M. Hetzel, H. Schirrmeister, G. Halter, P. Moller, C. Kratochwil, A. Wahl, G. Glatting, F. M. Mottaghy, T. Mattfeldt, B. Neumaier, S. N. Reske, Eur. J. Nucl. Med. Mol. Imaging 2005, 32, 525-533.
72. **Imaging of activated microglia with PET and C-11 PK 11195 in corticobasal degeneration**  
K. Henkel, J. Karitzky, M. Schmid, I. Mader, G. Glatting, J. W. Unger, B. Neumaier, A. C. Ludolph, S. N. Reske, G. B. Landwehrmeyer, Movement Disorders 2004, 19, 817-821.
73. **F-18 3'-Deoxy-3'-Fluorothymidine-PET in NHL patients: Whole-body biodistribution and imaging of lymphoma manifestations - a pilot study**  
I. Buchmann, B. Neumaier, M. Schreckenberger, S. Reske, Cancer Biotherapy and Radiopharmaceuticals 2004, 19, 436-442.
74. **F-18 3-deoxy-3'-fluorothymidine positron emission tomography: Alternative or diagnostic adjunct to 2- F-18 -fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?**  
G. Halter, A. K. Buck, H. Schirrmeister, I. Wurziger, F. Liewald, G. Glatting, B. Neumaier, L. Sunder-Plassmann, S. N. Reske, M. Hetzel, Journal of Thoracic and Cardiovascular Surgery 2004, 127, 1093-1099.

75. **Lymph node staging in lung cancer using F-18 FDG-PET**  
G. Halter, A. K. Buck, H. Schirrmeister, E. Aksoy, F. Liewald, G. Glatting, B. Neumaier, B. Muhling, K. Nussle-Kugele, M. Hetzel, L. Sunder-Plassmann, S. N. Reske, Thoracic and Cardiovascular Surgeon 2004, 52, 96-101.
76. **Imaging proliferation in lung tumors with PET: F-18-FLT versus F-18-FDG**  
A. K. Buck, G. Halter, H. Schirrmeister, J. Kotzerke, I. Wurziger, G. Glatting, T. Mattfeldt, B. Neumaier, S. N. Reske, M. Hetzel, J. Nucl. Med. 2003, 44, 1426-1431.
77.  **$^3\text{-}^3\text{-F-18 fluoro-}^3\text{-deoxythymidine ( F-18 -FLT)$  as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease**  
M. Wagner, U. Seitz, A. Buck, B. Neumaier, S. Schultheiss, M. Bangerter, M. Bommer, F. Leithauser, E. Wawra, G. Munzert, S. N. Reske, Cancer Res. 2003, 63, 2681-2687.
78. **Evaluation of pyrimidine metabolising enzymes and in vitro uptake of  $^3\text{-}^3\text{-F-18 fluoro-}^3\text{-deoxythymidine ( F-18 FLT)$  in pancreatic cancer cell lines**  
U. Seitz, M. Wagner, B. Neumaier, E. Wawra, G. Glatting, G. Leder, R. M. Schmid, S. N. Reske, Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1174-1181.
79. **Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer**  
J. Kotzerke, B. G. Volkmer, B. Neumaier, J. E. Gschwend, R. E. Hautmann, S. N. Reske, Eur. J. Nucl. Med. Mol. Imaging 2002, 29, 1380-1384.
80.  **$^3\text{-deoxy-}^3\text{-F-18 fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules$**   
A. K. Buck, H. Schirrmeister, M. Hetzel, M. von der Heide, G. Halter, G. Glatting, T. Mattfeldt, F. Liewald, S. N. Reske, B. Neumaier, Cancer Res. 2002, 62, 3331-3334.
81. **PET for prostate cancer imaging: Still a quandary or the ultimate solution?**  
J. Kotzerke, J. E. Gschwend, B. Neumaier, J. Nucl. Med. 2002, 43, 200-202.
82. **In vivo evaluation of  $^5\text{-F-18 fluoro-}^2\text{-deoxyuridine}$  as tracer for positron emission tomography in a murine pancreatic cancer model**  
U. Seitz, M. Wagner, A. T. Vogg, G. Glatting, B. Neumaier, F. R. Greten, R. M. Schmid, S. N. Reske, Cancer Res. 2001, 61, 3853-3857.
83. **Validation of myocardial blood flow estimation with nitrogen-13 ammonia PET by the argon inert gas technique in humans**  
J. Kotzerke, G. Glatting, J. van den Hoff, M. Hoher, B. Neumaier, J. Wohrle, S. N. Reske, European Journal of Nuclear Medicine 2001, 28, 340-345.
84. **Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation**  
S. N. Reske, D. Bunjes, I. Buchmann, U. Seitz, G. Glatting, B. Neumaier, J. Kotzerke, A. Buck, H. Martin, H. Dohner, L. Bergmann, European Journal of Nuclear Medicine 2001, 28, 807-815.
85. **Experience with carbon-11 choline positron emission tomography in prostate carcinoma**  
J. Kotzerke, J. Prang, B. Neumaier, B. Volkmer, A. Guhlmann, K. Kleischmidt, R. Hautmann, S. N. Reske, European Journal of Nuclear Medicine 2000, 27, 1415-1419.
86. **In vivo imaging of activated microglia using C-11 PK11195 and positron emission tomography in patients after ischemic stroke**  
A. Gerhard, B. Neumaier, E. Elitok, G. Glatting, V. Ries, R. Tomczak, A. C. Ludolph, S. N. Reske, Neuroreport 2000, 11, 2957-2960.



87. **Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: Differences in dosimetry and biokinetics of Re-188- and Tc-99m-labeled anti-NCA-95 MAbs**  
J. Kotzerke, G. Glatting, U. Seitz, M. Rentschler, B. Neumaier, D. Bunjes, C. Duncker, D. Dohr, L. Bergmann, S. N. Reske, J. Nucl. Med. 2000, 41, 531-537.
88. **Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia**  
U. Seitz, B. Neumaier, G. Glatting, J. Kotzerke, D. Bunjes, S. N. Reske, European Journal of Nuclear Medicine 1999, 26, 1265-1273.
89. **Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus F-18 PET**  
H. Schirrmeister, A. Guhlmann, K. Elsner, J. Kotzerke, G. Glatting, M. Rentschler, B. Neumaier, H. Trager, K. Nussle, S. N. Reske, J. Nucl. Med. 1999, 40, 1623-1629.
90. **Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography**  
H. Schirrmeister, A. Guhlmann, J. Kotzerke, C. Santjohanser, T. Kuhn, R. Kreienberg, P. Messer, K. Nussle, K. Elsner, G. Glatting, H. Trager, B. Neumaier, C. Diederichs, S. N. Reske, Journal of Clinical Oncology 1999, 17, 2381-2389.
91. **In vivo imaging of activated microglia using C-11 PK 11195 and positron emission tomography in multiple sclerosis**  
V. Ries, B. Neumaier, J. Schwarz, A. Grieser, A. Gerhard, R. Tomczak, A. C. Ludolph, S. N. Reske, Neurology 1999, 52, A354-A354.
92. **Ternary complex formation of lanthanides and radiolanthanides with phosphate and serum proteins**  
B. Neumaier, F. Rosch, Radiochim. Acta 1999, 84, 201-204.
93. **Ternary complex formation between yttrium, phosphate and serum proteins**  
B. Neumaier, F. Rosch, Radiochim. Acta 1998, 81, 171-177.
94. **Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography**  
F. Rosch, H. Herzog, C. Plag, B. Neumaier, U. Braun, H. W. MullerGartner, G. Stocklin, European Journal of Nuclear Medicine 1996, 23, 958-966.
95. **RADIOCHEMICAL STUDY OF THE BI-209(P,BE-7)HG-203-PROCESS FROM 20 TO 70 MEV VIA IDENTIFICATION OF THE EMITTED PARTICLE (BE-7) AND THE PRODUCT NUCLEUS (HG-203)**  
B. Neumaier, F. Rosch, S. M. Qaim, G. Stocklin, Radiochim. Acta 1994, 65, 1-7.